TAKHZYRO 300 mg, solution for injection in a pre-filled syringe syringe, 2 ml
Active ingredients: Lanadelumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 2 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TAKHZYRO 300 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue(s) préremplie(s) en verre de 2 ml
- Marketing authorisation holder
- TAKEDA PHARMACEUTICALS INTERNATIONAL (IRLANDE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Apr 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63473155CIP73021260CIP133400930212608Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LANADÉLUMABsolution | 300 mg · une seringue préremplie de 2 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.